Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ
Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies valued at more than $24 million, as of Friday's closing price; Plans partial distribution to shareholders
截至週五收盤價，Ehave擁有約9,793,754股Mycotopia Therapia股票，價值超過2400萬美元；計劃向股東部分分配
MIAMI, May 23, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the "Company"), a leading healthcare services and technology company, announced today that its Mycotopia Therapies (OTC: TPIA) subsidiary has signed a definitive agreement to complete a triangular merger with Ei.Ventures, an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology, to form PSLY.COM. The companies anticipate closing the transaction on or about July 30, 2022.
邁阿密，2022年5月23日（GLOBE NEWSWIRE）——領先的醫療保健服務和科技公司Ehave, Inc.（OTC Pink：EHVVF）（以下簡稱 “公司”）今天宣佈，其Mycotopia Therapies（場外交易代碼：TPIA）子公司已簽署最終協議，完成與通過精神活性化合物、營養品增強心理健康的早期科技公司Ei.Ventures的三角合併還有技術，組成了 PSLY.COM。兩家公司預計將在2022年7月30日左右完成交易。
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies, which was valued around $28.4 million at the close of business Friday. As of May 16, 2022 Ehave currently has 276,775,899 shares outstanding, which values Ehave's stake in Mycotopia Therapies at more than $0.10 per share. In addition to Ehave's Mycotopia Therapies stake, the company owns its KetaDASH subsidiary, MetaHealthU, and is developing partnerships with SelfDecode, COGAPPS, GoMeyra, and Vastmindz.
Ehave擁有Mycotopia Therapia Therapis的約9,793,754股股份，截至週五收盤時，該股的價值約爲2,840萬美元。截至2022年5月16日，Ehave目前有276,775,899股已發行股份，估值Ehave在Mycotopia Therapis的股份超過每股0.10美元。除了Ehave的Mycotopia Therapis股份外，該公司還擁有其KetaDash子公司MetaHealthU，並正在與SelfDecode、COGAPPS、GoMeyra和Vastmindz建立合作伙伴關係。
The transaction between Mycotopia Therapies and Ei.Ventures will be structured as a triangular merger. The two companies will form a new holding company, PSLY.COM, and operate as subsidiaries after the merger. PSLY.COM will apply for a NASDAQ listing. Mycotopia Therapies primary focus is on mushroom and psychedelic opportunities. The company has been performing most of its research in Jamaica, where psilocybin is legal, as well as working with one of the largest cannabis labs in the Netherlands to develop psychedelics to jointly license certain molecules to be used in psychedelic medicine. Ei.Ventures' ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. By leveraging blockchain, emerging technologies and the Metaverse, Ei.Ventures intends to create a safe, efficient, and secure way to provide telehealth services in general, as well as for psychoactive therapeutics.
Mycotopia Therapia Therapis和Ei.Ventures之間的交易將結構爲三角合併。兩家公司將組建新的控股公司PSLY.COM，並在合併後作爲子公司運營。PSLY.COM將申請在納斯達克上市。Mycotopia Therapias 的主要重點是蘑菇和迷幻的機會。該公司的大部分研究都在牙買加進行，那裏的迷幻藥是合法的，並與荷蘭最大的大麻實驗室之一合作開發迷幻藥，以共同許可某些分子用於迷幻藥物。Ei.Ventures的目標是提供政府批准的治療方案，以應對當前的全球心理健康疫情。通過利用區塊鏈、新興技術和元宇宙，Ei.Ventures打算創造一種安全、高效和可靠的方式來提供一般的遠程醫療服務以及精神活性療法。
Ben Kaplan, CEO of Ehave, Inc., said, "The statistics on the declining state of mental health in America are devastating. Globally, the statistics are even more bleak. Ei.Ventures recently completed a successful Reg A offering, which raised over $25 million. Their plan is not only to profit from delivering governmental approved therapeutic treatment options that address the current global mental healthcare crisis, but to provide solutions for the millions of people who want to improve their mental health. Not only will this transaction afford Ei.Ventures with better opportunities to raise capital in order to execute its business plan, it is a fantastic opportunity to monetize Ehave's Mycotopia Therapies asset for our shareholders."
Ehave, Inc. 首席執行官本·卡普蘭說：“關於美國心理健康狀況下降的統計數據是毀滅性的。在全球範圍內，統計數據更加慘淡。Ei.Ventures最近成功完成了Reg A發行，籌集了超過2500萬美元的資金。他們的計劃不僅是通過提供政府批准的應對當前全球心理健康危機的治療方案中獲利，而且還要爲數百萬想要改善心理健康的人提供解決方案。這筆交易不僅將爲Ei.Ventures提供更好的籌集資金以執行其商業計劃的機會，而且也是爲我們的股東通過Ehave的Mycotopia Therapia Therapia資產獲利的絕佳機會。”
In America, 52.9 million people, or 21% of U.S. adults, experienced mental illness in 2020, 14.2 million people, or 5.6% of U.S. adults, experienced serious mental illness in 2020. Even more alarming is that 16.5% of U.S. youth aged 6-17 experienced a mental health disorder in 2016, 6.7% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2020, and suicide has emerged as the 2nd leading cause of death among people aged 10-34.
在美國，2020年有5,290萬人（佔美國成年人的21％）患有精神疾病，2020年有1,420萬人（佔美國成年人的5.6％）患有嚴重的精神疾病。更令人震驚的是，2016年有16.5％的6-17歲美國年輕人患有精神疾病，2020年有6.7％的美國成年人同時患有藥物濫用障礙和精神疾病，自殺已成爲10-34歲人羣的第二大死因。
Ehave CEO Ben Kaplan continued, "As far as our Ehave shareholders are concerned, this business combination represents the culmination of monetizing our Mycotopia Therapies asset. At the end of December 2020, we announced we would reposition Mycotopia Therapies asset by merging it with 20/20 Global. We closed the transaction in January 2021, and applied to FINRA to change the name of the company from 20/20 Global to Mycotopia Therapies. Approximately one-year later, I announced plans to merge with Ei.Ventures and create PSLY.com in this transaction valued at more than $380 million. In addition to receiving shares of PSLY.com, our Ehave shareholders still own our growing KetaDASH subsidiary, MetaHealthU, and our developing partnerships with incredible companies like SelfDecode, COGAPPS, GoMeyra, and Vastmindz."
Ehave首席執行官本·卡普蘭繼續說：“就我們的Ehave股東而言，這種業務合併代表了通過我們的Mycotopia Therapia資產獲利的高潮。2020年12月底，我們宣佈將重新定位Mycotopia Therapias 資產，將其與20/20 Global合併。我們於2021年1月完成了交易，並向美國金融監管局申請將公司名稱從20/20 Global更改爲Mycotopia Therapies。大約一年後，我宣佈計劃與Ei.Ventures合併，在這筆價值超過3.8億美元的交易中創建PSLY.com。除了獲得PSLY.com的股份外，我們的Ehave股東仍然擁有我們不斷增長的KetaDash子公司MetaHealthU，以及我們與SelfDecode、COGAPPS、Gomeyra和Vastmindz等令人難以置信的公司不斷髮展的合作伙伴關係。”
Ehave will issue an additional press release, as well as file the required documents with the SEC, discussing distribution of Mycotopia Therapies/PSLY.COM shares to shareholders, as well as a timeline.
Ehave將發佈另一份新聞稿，並向美國證券交易委員會提交所需文件，討論向股東分配Mycotopia Therapies/psly.com股票以及時間表。
About Ehave, Inc.
關於 Ehave, Inc.
Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at: .
Ehave是一家領先的醫療保健服務和技術公司，致力於通過設計用於治療大腦健康的新化合物和新的治療方案，將迷幻藥轉化爲治療藥物。與我們的科學家和心理健康專業人員網絡一起，我們的使命是爲患者創造安全有效的治療方法，以解決多種心理健康問題，利用臨床數據來幫助我們實現最佳的患者療效。Ehave的業務遍及整個美國、加拿大、牙買加和澳大利亞。有關Ehave的更多信息，請訪問公司的網站：:.
About Mycotopia Therapies
關於真菌托邦療法
Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company's website at:
Mycotopia Therapies 專注於幫助您治癒和恢復生活。您的康復之旅是了解病因，並通過迷幻增強的心理治療，與專業的心理健康從業人員團隊和尖端技術相結合，致力於心理健康。迷幻療法是一種提供治療的整體和精神方法，多年來一直顯示出成功的治療方法。有關 Mycotopia Therapies 的更多信息可在公司網站上找到，網址爲：
About Ei.Ventures Inc.:
Ei.Ventures Inc. is an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology. Ei is leveraging blockchain, emerging technologies and the Metaverse to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. It is the goal of Ei to utilize the development of these technologies, to create a safe, efficient, and secure way to provide telehealth services in general and specifically to the psychoactive therapeutics. Additional information on Ei can be found on the Ei's website at:
關於 Ei.Ventures Inc.：
Ei.Ventures Inc. 是一家早期科技公司，通過精神活性化合物、營養品和技術來增強心理健康。Ei正在利用區塊鏈、新興技術和元宇宙來提供政府批准的治療方案，以應對當前的全球心理健康疫情。Ei的目標是利用這些技術的發展，創造一種安全、高效和可靠的方式來提供一般的遠程醫療服務，特別是向精神活性療法患者提供遠程醫療服務。有關Ei的更多信息，請訪問Ei的網站，網址爲：
Forward-Looking Statement Disclaimer
前瞻性聲明免責聲明
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,
本新聞稿包含1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”。此類陳述前面可能有 “打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“項目”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛力” 或類似詞語。前瞻性陳述基於某些假設，受各種已知和未知風險和不確定性的影響，其中許多風險和不確定性超出了公司的控制範圍，無法預測或量化，因此，實際結果可能與此類前瞻性陳述所表達或暗示的結果存在重大差異：（i）公司研究、製造和其他開發工作的啓動、時機、進展和結果；（ii）公司推進其產品以成功完成開發和商業化的能力化;(iii) 公司產品的製造、開發、商業化和市場接受度；(iv) 缺乏足夠的資金爲產品開發和業務運營提供資金；(v) 公司行業內具有競爭力的公司和技術以及競爭產品的推出；(vi) 公司建立和維持公司合作的能力；(vii) 關鍵管理人員的流失；(viii) 公司能夠建立和維持的保護範圍涵蓋其產品的知識產權，以及其在不侵犯他人知識產權的情況下開展業務的能力；(ix) 可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法；以及 (x) 難以預測美國食品和藥物管理局及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求，否則公司沒有義務更新任何書面或口頭的前瞻性陳述。有關公司以及可能影響前瞻性陳述實現的風險因素的更多詳細信息包含在Ehave, Inc.的 “風險因素” 標題下。於2015年9月24日向美國證券交易委員會（SEC）提交的經修訂的F-1表格註冊聲明，該聲明可在美國證券交易委員會的網站上查閱，
For Media and Investor Relations, please contact:
有關媒體和投資者關係事宜，請聯繫：
David L. Kugelman
大衛·L·庫格爾曼
(866) 692-6847 Toll Free - U.S. & Canada
(866) 692-6847 免費電話——美國和加拿大
(404) 281-8556 Mobile and WhatsApp
(404) 281-8556 手機和 WhatsApp
Email: Ir@Ehave.com
電子郵件：Ir@Ehave.com
Skype: kugsusa
Skype：kugsusa
譯文內容由第三人軟體翻譯。